|
Studienname/Sponsor
|
Entität(en)
|
Prüfsubstanz
|
42756493BLC1003
Phase I Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions
|
Bladder Cancer
|
Erdafitinib
|
75276617ALE1002
A Phase 1b/2 Study of JNJ-75276617 in Combination with Standard Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations)
|
AML
|
Menin-KMT2A Inhibitor
|
20150161 Amgen
Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia.
|
AML, Multiple Myeloma
|
MCL1 Inhibitor
|
20180257 Amgen
A Phase 1b Open-label Study to Investigate the Safety and Pharmacoki-netics of Administration of Subcutaneous Blinatumomab for the Treatment of adults with Relapsed or Refractory B cell Precursor Acute Lympho-blastic Leukemia (R/R B-ALL).
|
ALL
|
Anti-CD19 bispezifischer AK
|
BI 1403-0002
Phase Ia/1b, openlabel,dose-escalation Study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091 (ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors
|
Solide Tumore
|
BI 907828, Ezabenlimab
|
BO43243
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
|
Relapsed or Refractory CLL
|
Mosenutuzumab, Anti-CD20 bispezifischer AK
|
CPDR001x2x01b Novartis
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments.
|
Solide Tumore
|
Check point inhibitor
|
SCO101-001
A Phase 2 Trial of SCO-101 in combination with FOLFIRI for Patients with Metastatic Colorectal Cancer (mCRC) with acquired Resistance to FOLFIRI
|
Metastatic Colorectal Cancer
|
SCO-101 in combination with FOLFIRI
|
CADPT01C12101 Novartis
A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select drug combinations in adult patients with advanced or metastatic BRAF V600 colorectal cancer.
|
BRAF V600 colon cancer
|
Dabrafenib mit ERK1/2 inhibitor
|
IMA401-101
A Phase 1/2a First-in-human Study to Evaluate the Safety, Tolerability and Efficacy of IMA401, a bispecific T cell engaging receptor molecule (TCER®) in patients with recurrent and/or refractory solid tumors
|
Solid Tumors
|
bispecific T cell engaging receptor molecule
|
IMGN632-0802
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia.
|
AML (CD123 pos.)
|
Anti-CD123 ADC
|
NOA-26 - IT-PD1
Intrathecal application of PD1 antibody in metastatic solid tumors with leptomeningeal disease
|
Leptomeningeal disease in primary tumors with authorized indication for intravenous treatment with nivolumab, pembrolizumab or atezolizumab
|
Intrathecal application of the PD1 antibody nivolumab
|
UC02-123-01
Multicenter, open-label, adaptive design phase I trial with genetically modified T-cells carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in combination with CD123 target module (TM123) for the treatment of patients with hematologic and lymphatic malignancies positive for CD12.
|
AML, B-ALL, BPDCN (CD123 pos.)
|
CD123 CAR-T-cell
|
UC02-PSMA-01
Multicenter, Open-label, Adaptive Design Phase I Trial with Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination with PSMA peptide Target Module (TMpPSMA) for the Treatment of Patients with Progressive Disease after Standard Systemic Therapy in Cancers with Positive PSMA Marker.
|
PSMA pos. cancer i.e. prostate cancer
|
PSMA peptide CAR-T-cell
|
GMALL-BLIVEN
An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)
|
Relapsed/Refractory B cell precursor acute lymphoblastic leukemia
|
Venetoclax
|
BO41932 TAPISTRY
A Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay.
|
unresectable, locally advanced or metastatic solid tumors
|
Entrectinib, Alectinib, Inavolisib, Pralsetinib
|
